Bhardwaj, N., Friedlander, P., Pavlick, A., Ernstoff, M., Gastman, B., Hanks, B., … Fling, S. (2017). A dendritic cell targeting NY-ESO-1 vaccine significantly augments early and durable immune responses in melanoma patients pretreated with human Flt-3 Ligand. In JOURNAL FOR IMMUNOTHERAPY OF CANCER (Vol. 5). BMC.

Bhardwaj, Nina, Philip Friedlander, Anna Pavlick, Marc Ernstoff, Brian Gastman, Brent Hanks, Mark Albertini, et al. “A dendritic cell targeting NY-ESO-1 vaccine significantly augments early and durable immune responses in melanoma patients pretreated with human Flt-3 Ligand.” In JOURNAL FOR IMMUNOTHERAPY OF CANCER, Vol. 5. BMC, 2017.

Bhardwaj N, Friedlander P, Pavlick A, Ernstoff M, Gastman B, Hanks B, et al. A dendritic cell targeting NY-ESO-1 vaccine significantly augments early and durable immune responses in melanoma patients pretreated with human Flt-3 Ligand. In: JOURNAL FOR IMMUNOTHERAPY OF CANCER. BMC; 2017.

Bhardwaj, Nina, et al. “A dendritic cell targeting NY-ESO-1 vaccine significantly augments early and durable immune responses in melanoma patients pretreated with human Flt-3 Ligand.” JOURNAL FOR IMMUNOTHERAPY OF CANCER, vol. 5, BMC, 2017.

Bhardwaj N, Friedlander P, Pavlick A, Ernstoff M, Gastman B, Hanks B, Albertini M, Luke J, Yellin M, Keler T, Davis T, Vitale L, Blazquez A, Morishima C, Danaher P, Warren S, Salim B, Hess B, D’Amico L, Lundgren L, Disis N, Cheever M, Fling S. A dendritic cell targeting NY-ESO-1 vaccine significantly augments early and durable immune responses in melanoma patients pretreated with human Flt-3 Ligand. JOURNAL FOR IMMUNOTHERAPY OF CANCER. BMC; 2017.